Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

Event	H.C. Wainwright 25th Annual Global Investment Conference
Date	September 12, 2023
Time	12:00 PM - 12:30 PM ET
Location	New York
Webcast Link	https://journey.ct.events/view/ac177925-4d81-4425-b349-9491973f53cb

Event	2023 Cantor Global Healthcare Conference
Date	September 27, 2023
Time	8:00 AM - 8:30 AM ET
Location	New York
Webcast Link	https://wsw.com/webcast/cantor19/nvct/2113419

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating the activity of NXP800 as a potential treatment for platinum resistant, ARID1a-mutated ovarian carcinoma. The U.S. Food and Drug Administration (“FDA”) granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The NXP900 Investigational New Drug Application has been cleared by the FDA and a Phase 1a dose escalation study is expected to begin in Q3 2023.

Company Contact

Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
[email protected]

Media Relations Contact

Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
[email protected] 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Le Comble Reports MOVA Residences by B&B Italia Reaches 75% Sold in Panama City
• Crypto Price Today Highlights Solana Momentum as Apeing’s New Crypto Presale Stage 3 Almost Sold Out
• NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS